Par Drugs (India) Investor Sentiment

PAR Stock   288.35  4.15  1.42%   
About 62% of Par Drugs' investor base is looking to short. The analysis of overall sentiment of trading Par Drugs And stock suggests that many investors are alarmed at this time. The current market sentiment, together with Par Drugs' historical and current headlines, can help investors time the market. In addition, many technical investors use Par Drugs And stock news signals to limit their universe of possible portfolio assets.
Par Drugs stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Par daily returns and investor perception about the current price of Par Drugs And as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at news.google.com         
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to...
Google News at Macroaxis
over six months ago at news.google.com         
Stock market update Stocks that hit 52-week highs on NSE - The Economic Times
Google News at Macroaxis
over six months ago at news.google.com         
Stock market update Stocks that hit 52-week lows on NSE - The Economic Times
Google News at Macroaxis
over six months ago at news.google.com         
Which ASX companies are resurrecting abandoned drugs Part 3 - Stockhead
Google News at Macroaxis
over six months ago at news.google.com         
Improved Earnings Required Before Par Drugs and Chemicals Limited Stocks 29 percent Jump Looks Justi...
Google News at Macroaxis
over six months ago at news.google.com         
Stock market update Nifty Auto index falls 0.05 percent in a weak market - The Economic Times
Google News at Macroaxis
over six months ago at news.google.com         
Stock market update Nifty Auto index falls 0.66 percent in a weak market - The Economic Times
Google News at Macroaxis
over six months ago at news.google.com         
Heres Why We Think Par Drugs and Chemicals Might Deserve Your Attention Today - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Heres Why We Think Par Drugs and Chemicals Might Deserve Your Attention Today - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Barbiturate Drugs Market Size, Industry Analysis, 2024 - 2032 - Global Market Insights
Google News at Macroaxis
over six months ago at news.google.com         
Par recalls batch of Remodulin generic over particulate concerns - FiercePharma
Google News at Macroaxis
over six months ago at news.google.com         
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Po...
Google News at Macroaxis
over six months ago at news.google.com         
Par Drugs Chemicals standalone net profit declines 6.91 percent in the June 2022 quarter - Indiainfo...
Google News at Macroaxis
over six months ago at news.google.com         
Par Drugs Standalone December 2023 Net Sales at Rs 24.00 crore, up 4.65 percent Y-o-Y - Moneycontrol
Google News at Macroaxis
over six months ago at news.google.com         
Par Drugs and Chemicals Third Quarter 2024 Earnings EPS 2.78 - Simply Wall St
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Par Drugs that are available to investors today. That information is available publicly through Par media outlets and privately through word of mouth or via Par internal channels. However, regardless of the origin, that massive amount of Par data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Par Drugs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Par Drugs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Par Drugs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Par Drugs alpha.

Par Drugs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Is Par Drugs and Chemicals Limiteds Recent Stock Performance Tethered To Its Strong Fundamentals - Simply Wall St
10/17/2024
2
Breakout stocks to buy or sell FSL to Indian Bank Sumeet Bagadia recommends five shares to buy today Stock Market News - Mint
10/29/2024

Complementary Tools for Par Stock analysis

When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories